CareRx Corporation

TSX:CRRX.TO

Medical - Care Facilities

Healthcare
$3.21 +0.63%

+$0.02 today

Market cap
$203.06M
Beta
0.62
P/E (TTM)
7.4
EPS (TTM)
$0.43
Dividend yield
1.88%
52W Low $2.70High $4.00

Volume 0.01M

Average 0.04M

CRRX.TO Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

CareRx CorporationTSX: CRRX.TO

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development remains negative

Q1 FY2026 research & development was CA$0, compared with CA$0 a year earlier. Trailing-twelve-month research & development was CA$0.

Context

  • Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly research & development holds near CA$0 or moves back toward the trailing-twelve-month quarterly average of CA$0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$0— QoQ
Last fiscal yearDec 2025
CA$0— YoY
LTMMar 2026
CA$0— YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Research & Development history

CAD · from the income statement

Latest · FY2025
0 CAD
Year-over-year change
—

Research & Development vs competitors

How CRRX.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Research & development amounts to 0.0% of revenue for CRRX.TO, versus a peer median of 0.1%.
CRRX.TO Competitors
Research & Development for CRRX.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PRN.TOProfound Medical Corp.LTM Mar 2026$20.97M USD+17.5%+12.6%111.8%
HBP.TOHelix BioPharma Corp.LTM Apr 2026CA$1.62M CAD-72.8%-7.7%—
XLY.TOAuxly Cannabis Group Inc.LTM Mar 2026CA$267K CAD+62.8%—0.2%
CRRX.TOCareRx CorporationLTM Mar 2026CA$0 CAD——0.0%
DR.TOMedical Facilities CorporationLTM Mar 2026$0 USD——0.0%
HLS.TOHLS Therapeutics Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding CRRX.TO) —+17.5%+2.4%0.1%

Competitors are the stored peer set for CRRX.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue262.63M381.73M370.75M366.71M370.24M
Cost of Revenue187.35M271.79M286.02M258.65M277.61M
Gross Profit75.28M109.93M84.72M108.06M92.63M
Gross Margin28.7%28.8%22.9%29.5%25.0%
Research & Development00000
Selling, General & Admin70.52M102.55M77.5M32.75M34.23M
Operating Expenses70.47M82.24M100.03M103.54M80.75M
Depreciation & Amortization15.39M20.07M19.98M19.19M18.33M
EBITDA9.01M(610K)24.65M23.9M30.22M
EBITDA Margin3.4%-0.2%6.6%6.5%8.2%
Operating Income(3.31M)(21.94M)4.67M4.53M11.88M
Operating Margin-1.3%-5.7%1.3%1.2%3.2%
Interest Income58K278K1.26M63K161K
Interest Expense17.35M15.22M14.27M9.18M6.84M
Other Income / Expenses(20.43M)(13.95M)(14.27M)(8.99M)(8.53M)
Income Before Tax(23.74M)(35.9M)(9.6M)(4.47M)3.35M
Pre-Tax Margin-9.0%-9.4%-2.6%-1.2%0.9%
Income Tax Expense(1.01M)(1.54M)(4.19M)32K(22.77M)
Net Income(22.73M)(34.35M)(5.41M)(4.5M)26.13M
Net Margin-8.7%-9.0%-1.5%-1.2%7.1%
EPS (Basic)(0.65)(0.72)(0.09)(0.07)0.42
EPS (Diluted)(0.65)(0.72)(0.09)(0.07)0.41
Weighted Avg Shares34.86M47.6M57.35M60.25M62.73M
Weighted Avg Shares (Diluted)34.86M47.6M57.35M60.25M64.49M

CareRx Corporation

TSX:CRRX.TO

Intrinsic Alpha fair value

Locked

Current Price

$3.21

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.